V 0162

Drug Profile

V 0162

Alternative Names: V0162; VO-162

Latest Information Update: 25 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Developer Pierre Fabre; SGS
  • Class Phenothiazines; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Suspended Overactive bladder
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Urinary incontinence

Most Recent Events

  • 25 Aug 2015 Discontinued - Phase-II for Urinary incontinence in Europe (unspecified route)
  • 25 Aug 2015 No recent reports on development identified - Phase-I/II for Chronic obstructive pulmonary disease in Belgium and France (Inhalation)
  • 30 Sep 2013 Phase-II clinical trials in Asthma in Germany (Unspecified route) (NCT01951222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top